Odyssey Therapeutics Appoints Jolie M. Siegel as Executive Vice President, General Counsel [Yahoo! Finance]
C4 Therapeutics, Inc. (CCCC)
NASDAQ:AMEX Investor Relations:
ir.chinacache.com
Company Research
Source: Yahoo! Finance
BOSTON, January 21, 2026 BUSINESS WIRE Odyssey Therapeutics, Inc. , a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, today announced the appointment of Jolie M. Siegel, Executive Vice President, General Counsel. In this role, Ms. Siegel will lead Odyssey's legal, compliance, governance, and risk management functions, serving as a strategic partner to the executive team and Board of Directors. She will oversee corporate governance and compliance, securities, intellectual property, contractual and transactional matters as the company continues to advance its growing portfolio of immunology programs. "Jolie's appointment comes at an important stage in Odyssey's development," said Gary D. Glick, Ph.D., Founder and CEO of Odyssey Therapeutics. "As our portfolio advances and the company evaluates strategic
Show less
Read more
Impact Snapshot
Event Time:
CCCC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CCCC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CCCC alerts
High impacting C4 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CCCC
News
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Clinical trial results drove insider trading: SEC [Investment Executive - News]Investment Executive - News
- C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated PathwaysGlobeNewswire
- C4 Therapeutics (NASDAQ:CCCC) was given a new $5.00 price target on by analysts at Barclays PLC.MarketBeat
- C4 Therapeutics (NASDAQ:CCCC) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.MarketBeat
CCCC
Earnings
- 11/6/25 - Beat
CCCC
Sec Filings
- 1/16/26 - Form 4
- 1/14/26 - Form 8-K
- 1/5/26 - Form 4
- CCCC's page on the SEC website